Finally, nano‐DDSs provide a versatile platform for the co‐delivery of multiple therapeutic agents within a single nanocarrier at defined ratios.[15] This strategy facilitates synergistic interactions between STING agonists and other therapies, such as chemotherapeutics, radiotherapy sensitizers, immune checkpoint inhibitors, and photosensitizers, thereby broadening the therapeutic window and enhancing the potential for combined cancer treatments. This evidence concerns the gene STING1 and cancer.